Ohio MMCP Recalls Medical Marijuana for Failed Testing

Dec.09.2022

Ohio MMCP Recalls Medical Marijuana for Failed Testing

Ohio MMCP recalls medical marijuana due to failed testing. Investigation ongoing, updates on 2FIRSTS app.

On December 6th, the Ohio Medical Marijuana Control Program (MMCP) issued a voluntary product recall for medical marijuana that did not pass all necessary tests.

The affected plant material was produced by Green Investment Partners (GIP) and sold to pharmacies. These pharmacies initiated a recall and reported to MMCP that certain batches of cannabis were distributed and sold to patients without passing all nationally mandated yeast and mold tests.

The MMCP has launched an investigation and will release an executive summary after the investigation is complete.

2FIRSTS will continue to report on this topic, with further updates available on the "2FIRSTSAPP". Scan the QR code below to download the app.

#Drug testing #Medical marijuana dispensary #USA

This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

China Tobacco Regulation Shift：Policy Updates and Market Impact

China Tobacco Regulation Shift：Policy Updates and Market Impact

EVO NXT European Tobacco & NGP Exhibition

EVO NXT European Tobacco & NGP Exhibition

From myblu to Zone: Imperial Brands Refocuses NGP Strategy in HY26

From myblu to Zone: Imperial Brands Refocuses NGP Strategy in HY26

mperial Brands’ HY26 results point to a more selective NGP transition. The company is using cash flow from traditional tobacco to fund targeted investments in modern oral nicotine, heated tobacco and reusable vaping systems. Its decision to exit the legacy myblu vaping business in the U.S., while expanding Zone nicotine pouches. In Europe, Imperial’s NGP growth is being driven by a multi-category portfolio including blu, Pulze and Zone/Skruf.

Ispire Reports Fiscal Q3 2026 Revenue of $18.7 Million and Net Loss of $9.5 Million

Ispire Reports Fiscal Q3 2026 Revenue of $18.7 Million and Net Loss of $9.5 Million

Ispire Technology reported financial results on May 7, 2026, for the third quarter of fiscal 2026, covering the three months ended March 31, 2026. Revenue was $18.7 million, compared with $26.2 million in the third quarter of fiscal 2025 and $20.3 million in the prior quarter. Gross profit was $2.0 million, with gross margin of 10.7%. Net loss was $9.5 million, or $0.17 per share. The company said it held $18.0 million in cash as of March 31, 2026, up $468,000 sequentially.

May.08 by 2FIRSTS.ai

Altria Reports Q1 2026 Net Revenues of $5.43 Billion and 7.3% Growth in Adjusted Diluted EPS

Altria Reports Q1 2026 Net Revenues of $5.43 Billion and 7.3% Growth in Adjusted Diluted EPS

Altria Group reported its first-quarter 2026 results on April 30. Net revenues were $5.43 billion, up 3.2% year on year, while revenues net of excise taxes were $4.76 billion, up 5.3%. Reported diluted EPS was $1.30, up more than 100%, and adjusted diluted EPS was $1.32, up 7.3%.

May.06 by 2FIRSTS.ai

Philip Morris Limited Launches Delia to Expand IQOS Iluma Consumables Portfolio

Philip Morris Limited Launches Delia to Expand IQOS Iluma Consumables Portfolio

Philip Morris Limited has announced the launch of Delia, the latest addition to its portfolio of heated tobacco and zero-tobacco sticks exclusively compatible with the IQOS Iluma range.

Apr.03 by 2FIRSTS.ai

FDA Defines Enforcement Focus for Unauthorized E-Cigarettes and Nicotine Pouches

FDA Defines Enforcement Focus for Unauthorized E-Cigarettes and Nicotine Pouches

The U.S. Food and Drug Administration issued guidance on May 8, 2026, titled “Enforcement Priorities for Certain New Tobacco Products Marketed Without Premarket Authorization.” The document describes FDA enforcement policies for certain electronic nicotine delivery system products and nicotine pouch products marketed without premarket authorization.

May.09 by 2FIRSTS.ai

Disposable Vape Ban Shifts Purchasing Formats as UK Vape Volume Falls 10.3%

Disposable Vape Ban Shifts Purchasing Formats as UK Vape Volume Falls 10.3%

Data from convenience insight agency Talysis shows that the value of tobacco, vapes and smoking alternatives in the independent convenience sector fell by 4.4% in the first quarter of 2026, while volume fell by 7.8%. The vaping subcategory declined by 3.9% in value and 10.3% in volume over the same period. Talysis said the impact of the disposable vape ban continues to pressure turnover and footfall.

May.08 by 2FIRSTS.ai

Related Topics

News

Related Read

From myblu to Zone: Imperial Brands Refocuses NGP Strategy in HY26

From myblu to Zone: Imperial Brands Refocuses NGP Strategy in HY26

Ispire Reports Fiscal Q3 2026 Revenue of $18.7 Million and Net Loss of $9.5 Million

Ispire Reports Fiscal Q3 2026 Revenue of $18.7 Million and Net Loss of $9.5 Million

Altria Reports Q1 2026 Net Revenues of $5.43 Billion and 7.3% Growth in Adjusted Diluted EPS

Altria Reports Q1 2026 Net Revenues of $5.43 Billion and 7.3% Growth in Adjusted Diluted EPS

Philip Morris Limited Launches Delia to Expand IQOS Iluma Consumables Portfolio

Philip Morris Limited Launches Delia to Expand IQOS Iluma Consumables Portfolio

FDA Defines Enforcement Focus for Unauthorized E-Cigarettes and Nicotine Pouches

FDA Defines Enforcement Focus for Unauthorized E-Cigarettes and Nicotine Pouches

Disposable Vape Ban Shifts Purchasing Formats as UK Vape Volume Falls 10.3%

Disposable Vape Ban Shifts Purchasing Formats as UK Vape Volume Falls 10.3%